The Emerging Role of ABL Kinases in Solid Tumors

Trends in Cancer

Volumn 1, Issue 2, 2015, Pages 110-123

  Wang, Jun ^a   Pendergast, Ann Marie ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ABELSON KINASE 1; ABELSON KINASE 2; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME CONFORMATION; ENZYME METABOLISM; ENZYME REGULATION; GENOMICS; HUMAN; INTESTINE CANCER; KIDNEY CANCER; LEUKEMIA; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; OXIDATIVE STRESS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SOLID TUMOR; SOMATIC MUTATION; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 84956954278     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2015.07.004     Document Type: Review

References (84)

1. S. Wong, and O.N. Witte The BCR-ABL story: bench to bedside and back Annu. Rev. Immunol. 22 2004 247 306
2. C.A. Eide, and T. O'Hare Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors Curr. Hematol. Malig. Rep. 10 2015 158 166
3. J. Colicelli ABL tyrosine kinases: evolution of function, regulation, and specificity Sci. Signal. 3 2010 re6
4. E.K. Greuber, and et al. Role of ABL family kinases in cancer: from leukaemia to solid tumours Nat. Rev. Cancer 13 2013 559 571
5. S.S. Ganguly, and R. Plattner Activation of abl family kinases in solid tumors Genes Cancer 3 2012 414 425
6. W.D. Bradley, and A.J. Koleske Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts J. Cell Sci. 122 2009 3441 3454
7. S. Panjarian, and et al. Structure and dynamic regulation of Abl kinases J. Biol. Chem. 288 2013 5443 5450
8. O. Hantschel, and G. Superti-Furga Regulation of the c-Abl and Bcr-Abl tyrosine kinases Nat. Rev. Mol. Cell Biol. 5 2004 33 44
9. R. Plattner, and et al. A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1 Nat. Cell Biol. 5 2003 309 319
10. A.J. Koleske, and et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation Neuron 21 1998 1259 1272
11. P.L. Schwartzberg, and et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations Cell 65 1991 1165 1175
12. V.L. Tybulewicz, and et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene Cell 65 1991 1153 1163
13. Z. Qiu, and et al. c-Abl tyrosine kinase regulates cardiac growth and development Proc. Natl. Acad. Sci. U.S.A. 107 2010 1136 1141
14. E.M. Moresco, and et al. Integrin-mediated dendrite branch maintenance requires Abelson (Abl) family kinases J. Neurosci. 25 2005 6105 6118
15. B. Li, and et al. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation Nat. Genet. 24 2000 304 308
16. H.Y. Kua, and et al. c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression Nat. Cell Biol. 14 2012 727 737
17. S.L. Gourley, and et al. Loss of dendrite stabilization by the Abl-related gene (Arg) kinase regulates behavioral flexibility and sensitivity to cocaine Proc. Natl. Acad. Sci. U.S.A. 106 2009 16859 16864
18. E.K. Greuber, and A.M. Pendergast Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages J. Immunol. 189 2012 5382 5392
19. J.J. Gu, and et al. Defective T cell development and function in the absence of Abelson kinases J. Immunol. 179 2007 7334 7343
20. E.M. Chislock, and et al. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival Proc. Natl. Acad. Sci. U.S.A. 110 2013 12432 12437
21. D.M. Wetzel, and et al. The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection Mol. Cell. Biol. 32 2012 3176 3186
22. R. Ren Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia Nat. Rev. Cancer 5 2005 172 183
23. A.S. Advani, and A.M. Pendergast Bcr-Abl variants: biological and clinical aspects Leuk. Res. 26 2002 713 720
24. T. O'Hare, and et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia Nat. Rev. Cancer 12 2012 513 526
25. T. Pemovska, and et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation Nature 519 2015 102 105
26. B. Nagar, and et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 62 2002 4236 4243
27. J. Zhang, and et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 2010 501 506
28. K.G. Roberts, and et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia N. Engl. J. Med. 371 2014 1005 1015
29. H. Kawai, and et al. Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia Leuk. Res. 38 2014 1451 1459
30. E. De Braekeleer, and et al. ABL1 fusion genes in hematological malignancies: a review Eur. J. Haematol. 86 2011 361 371
31. K. De Keersmaecker, and et al. Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore Mol. Cell 31 2008 134 142
32. J. Lin, and R. Arlinghaus Activated c-Abl tyrosine kinase in malignant solid tumors Oncogene 27 2008 4385 4391
33. S.S. Ganguly, and et al. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression Oncogene 31 2012 1804 1816
34. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70
35. E. Cerami, and et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov. 2 2012 401 404
36. M.L. Sos, and et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions J. Clin. Invest. 119 2009 1727 1740
37. L. Simpson, and et al. Renal medullary carcinoma and ABL gene amplification J. Urol. 173 2005 1883 1888
38. T.E. Behbahani, and et al. Tyrosine kinase expression profile in clear cell renal cell carcinoma World J. Urol. 30 2012 559 565
39. T. Crnogorac-Jurcevic, and et al. Expression profiling of microdissected pancreatic adenocarcinomas Oncogene 21 2002 4587 4594
40. C.W. Wu, and et al. Arg tyrosine kinase expression in human gastric adenocarcinoma is associated with vessel invasion Anticancer Res. 23 2003 205 210
41. R. Li, and et al. Abl kinases regulate HGF/Met signaling required for epithelial cell scattering, tubulogenesis and motility PLoS ONE 10 2015 e0124960
42. L.S. Fiore, and et al. c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer Oncogene 33 2014 4508 4520
43. R.B. Jones, and et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays Nature 439 2006 168 174
44. A. Furlan, and et al. Abl interconnects oncogenic Met and p53 core pathways in cancer cells Cell Death Differ. 18 2011 1608 1616
45. C. Iavarone, and et al. Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene J. Biol. Chem. 281 2006 10567 10576
46. D. Matei, and et al. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation Clin. Cancer Res. 10 2004 681 690
47. X.N. Stahtea, and et al. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation Int. J. Cancer 121 2007 2808 2814
48. L.M. Packer, and et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia Cancer Cell 20 2011 715 727
49. M. Genander, and et al. Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression Cell 139 2009 679 692
50. C. Cortina, and et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells Nat. Genet. 39 2007 1376 1383
51. P. Kundu, and et al. An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth Sci. Transl. Med. 7 2015 281ra244
52. Z. Blanchard, and et al. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative PLoS ONE 9 2014 e95663
53. H. Gil-Henn, and et al. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo Oncogene 32 2012 2622 2630
54. C. Sourbier, and et al. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer Cancer Cell 26 2014 840 850
55. Y. Yang, and et al. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma PLoS ONE 8 2013 e72179
56. X. Sun, and et al. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species J. Biol. Chem. 275 2000 17237 17240
57. I.J. Fidler The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited Nat. Rev. Cancer 3 2003 453 458
58. P.S. Smith-Pearson, and et al. Abl kinases are required for invadopodia formation and chemokine-induced invasion J. Biol. Chem. 285 2010 40201 40211
59. C.C. Mader, and et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion Cancer Res. 71 2011 1730 1741
60. C. Chevalier, and et al. ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines PLoS ONE 10 2015 e0118854
61. M. Sonoshita, and et al. Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO Cancer Discov. 5 2015 198 211
62. M.T. Weigel, and et al. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer Breast Cancer Res. 14 2012 R78
63. H. Zhao, and et al. Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer Mol. Carcinogenesis 50 2011 383 389
64. Y.H. Lo, and et al. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016) Anticancer Res. 31 2011 789 795
65. J.T. Sims, and et al. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1 PLoS ONE 8 2013 e55509
66. J.T. Sims, and et al. STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner Biochem. Pharmacol. 78 2009 249 260
67. S. Gonfloni, and et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death Nat. Med. 15 2009 1179 1185
68. S. Gonfloni DNA damage stress response in germ cells: role of c-Abl and clinical implications Oncogene 29 2010 6193 6202
69. L.N. Puls, and et al. Current status of SRC inhibitors in solid tumor malignancies Oncologist 16 2011 566 578
70. T.J. Stuhlmiller, and et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains Cell Rep. 11 2015 390 404
71. J.S. Duncan, and et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer Cell 149 2012 307 321
72. H-Y. Kua, and et al. c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression Nat. Cell Biol. 14 2012 727 737
73. H. Zheng, and et al. PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis Cancer Cell 26 2014 358 373
74. J.J. Gu, and et al. Abl family kinases modulate T cell-mediated inflammation and chemokine-induced migration through the adaptor HEF1 and the GTPase Rap1 Sci. Signal. 5 2012 ra51
75. R.A. Cleary, and et al. Role of Abl in airway hyperresponsiveness and airway remodeling Respir. Res. 14 2013 105
76. P.C. Trampont, and et al. ShcA regulates thymocyte proliferation through specific transcription factors and a c-Abl-dependent signaling axis Mol. Cell. Biol. 35 2015 1462 1476
77. X. Sun, and et al. Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells Carcinogenesis 30 2009 2109 2116
78. D. Srinivasan, and R. Plattner Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells Cancer Res. 66 2006 5648 5655
79. K. Pietras, and et al. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting PLoS Med. 5 2008 e19
80. E.M. Chislock, and A.M. Pendergast Abl family kinases regulate endothelial barrier function in vitro and in mice PLoS ONE 8 2013 e85231
81. C. Raimondi, and et al. Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells J. Exp. Med. 211 2014 1167 1183
82. A. Sirvent, and et al. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells Biol. Cell 100 2008 617 631
83. Y. Bi, and et al. Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth Am. J. Pathol. 184 2014 2791 2802
84. U. Yaqoob, and et al. Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment Cancer Res. 72 2012 4047 4059